|
Age
|
56.6 ± 17.5
|
57.1 ± 16.1
|
0.876
|
|
Gender (male/female)
|
36/21
|
29/15
|
0.775
|
|
Immunocompromised (%)
|
28.1
|
22.7
|
0.543
|
|
APACHE II score, diagnosis day
|
22.6 ± 6.1
|
23.7 ± 5.1
|
0.506
|
|
SOFA score, diagnosis day
|
6.3 ± 3.7
|
5.9 ± 2.5
|
0.492
|
|
PaO2/FiO2 (mm Hg), diagnosis day
|
148.6 ± 62.0
|
134.1 ± 57.3
|
0.234
|
|
SOFA score, biopsy day
|
7.3 ± 3.9
|
6.6 ± 2.7
|
0.326
|
|
PaO2/FiO2 (mm Hg), biopsy day
|
158.5 ± 72.5
|
136.0 ± 59.9
|
0.099
|
|
PEEP (cm H2O), biopsy day
|
12.0 ± 3.0
|
11.5 ± 2.3
|
0.423
|
|
Tidal volume (mL), biopsy day
|
422.3 ± 95.4
|
422.4 ± 108.5
|
0.995
|
|
Duration from diagnosis to biopsy (days)
|
7.6 ± 6.7
|
7.7 ± 7.1
|
0.724
|
|
Operative complication rate (%)
|
10.5
|
15.9
|
0.423
|
|
Treatment changes after biopsy (%)
|
43.9
|
54.5
|
0.287
|
|
Hospital mortality (%)
|
71.9
|
45.5
|
0.007*
|
